ARCHIVES

mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approves Generic Capecitabine

September 20, 2013

Particle Therapy Program Would cost $600 million Over 10 Years for 16 Facilities, Clinical Trials

December 2, 1977

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

Scientists Brief Writers On Progress In Cancer Research

April 18, 1975

National Cancer Policy Forum Studies Modernization, Funding Of Cooperative Group Program.

July 11, 2008